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Fluoroquinolone resistance was detected in 12 of 370
Australian human Campylobacter isolates; 10 of these
were travel-associated, and for 2 isolates travel status was
unknown. No resistance was found in isolates known to be
locally acquired. In Australia, fluoroquinolones have not
been licensed for use in food production animals, a policy
that may have relevance for countries with fluoroquinolone-
resistant Campylobacter. 
I
n Australia, Campylobacter is the most commonly
reported bacterial foodborne pathogen with an annual
incidence of 125/100,000 population (1). Fluoroquinolone
resistance in this pathogen is recognized as an emerging
public health problem related to the use of these antimicro-
bial agents in food production animals. Data from many
regions (United States, Europe, and Thailand) that have
licensed fluoroquinolones for therapeutic use in animals
have shown that such use results in the emergence of fluo-
roquinolone resistance in Campylobacter jejuni and C. coli
isolates obtained from both humans and animals (2–4).
Increasing resistance in campylobacter may lead to infec-
tions that are unresponsive to antimicrobial drug treatment
and more severe disease. Smith (2) demonstrated that
resistant  C. jejuni caused more prolonged diarrhea in
patients than susceptible strains. 
Fluoroquinolone resistance may emerge during treat-
ment in humans (3); however, Smith (2) and others (5)
demonstrated that most detected resistant isolates come
from patients who have not been exposed to fluoro-
quinolones. Furthermore, as human-to-human transmis-
sion of campylobacter is rare, patients infected with resist-
ant campylobacter are not an important source of resist-
ance for other humans (4). 
In Australia, fluoroquinolones have never been licensed
for use in food production animals. Asmall amount is used
in companion animals: imports of enrofloxacin began in
1995, and 49 kg was used in the financial year 1996–97
(6). In contrast, the average use of quinolones in humans
was 3,200 kg per year from 1992 to 1997 (6). 
Australian data on fluoroquinolone resistance in human
Campylobacter isolates are limited. As part of a case-con-
trol study of risk factors for Campylobacter infection con-
ducted in New South Wales from 1999 to 2001, patients
infected with this pathogen were recruited, and informa-
tion on various exposures was obtained by telephone inter-
view. Patients were asked about local and international
travel in the 4 weeks before onset of diarrhea. Isolates
from patients were stored and subsequently tested for
resistance to 10 antimicrobial agents by using the National
Committee for Clinical Laboratory Standards method for
Helicobacter species (7). The Table shows proportions of
fluoroquinolone-resistant isolates from this case-control
study. In addition, results of two laboratory-based surveys
of antimicrobial resistance, one conducted on isolates from
Western Australia and one conducted on isolates from the
Australian Capital Territory, are included. In these last two
studies, information on overseas travel was sought retro-
spectively. Fluoroquinolone-resistant human Campylo-
bacter isolates were rarely detected in Australia. All
ciprofloxacin-resistant isolates detected in the three
regions were from patients who appeared to have acquired
their infection outside the country (Table). Two locally
acquired isolates in the New South Wales study were
resistant to nalidixic acid only (i.e., they were sensitive to
fluoroquinolones). 
As Campylobacter infection is zoonotic, the absence of
human, locally acquired infections attributable to fluoro-
quinolone-resistant organisms most likely reflects 1) the
lack of use of fluoroquinolones in Australian poultry (the
most common source for C. jejuni) and other potential
meat sources and 2) the presence of little or no viable
Campylobacter organisms on imported chicken, which has
been a source of resistant campylobacter infections in the
United Kingdom (5). Only cooked chicken products can be
imported into Australia. 
Fluoroquinolones are critical therapeutic agents for
many serious bacterial infections because, in many cases,
they may be the only active oral agents available.
Resistance following fluoroquinolone use can develop in
many gram-negative bacteria (campylobacter, salmonel-
lae, and Escherichia coli) carried by animals. These bacte-
ria can be present in food. If they subsequently cause
infections in humans (or transfer their resistance genes to
other bacteria), no effective antimicrobial agents may be
available for treatment when serious disease occurs. Thus,
their use in animals should be avoided. Australia has never
licensed the use of fluoroquinolone agents in livestock. In
contrast with other nations that have licensed their use,
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fluoroquinolone resistance in Campylobacter isolates and
subsequent infections in humans acquired from meats
eaten within the country have not emerged in Australia.
The Australian experience has implications for the contin-
ued licensing of these agents in other countries for food
production animals. 
Antimicrobial testing of isolates from the New South Wales
case-control study was funded by OzFoodNet, enhanced surveil-
lance program of the Department of Health and Ageing,
Australia.
Ms. Unicomb is an epidemiologist with OzFoodNet, the
Australian enhanced foodborne disease surveillance program
with particular involvement in studies of the risk factors for
campylobacter infection and subtyping methods for that organ-
ism.
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Table. Fluoroquinolone resistance data for Australian Campylobacter isolates 
Proportion
a of fluoroquinolone-resistant isolates (%) 
Study location 
Isolate source and 
collection period 
 
Total no. tested  Locally acquired  Overseas acquired  Unknown acquisition status 
New South Wales   Human feces 
1999–2001 
180
b  0/144 (0)  3
c/7 (43)  2
c/29 (6.9) 
Western Australia   Human feces 
1999–2000 
50
b    4
c  0/46 (0) 
Australian Capital Territory   Human feces/blood 
2001–2002 
140
d    3  0/137 (0) 
aNo. of resistant isolates by acquisition status/total no. isolates tested in acquisition status category. 
bTesting by agar dilution, Mueller-Hinton agar with 5% lysed sheep blood (7). 
cResistant to ciprofloxacin (MIC > 4 mg/L). 
dTesting by disc-susceptibility method (8). 